• Final patient enrolled in randomized, double-blind, placebo-controlled Phase 2 trial of SNT-4728 in isolated REM Sleep Behaviour Disorder (iRBD)
• iRBD is a strong predictor of Parkinson's disease and related neurodegenerative disorders
• Trial evaluating SNT-4728's ability to reduce neuroinflammation and improve iRBD symptoms

Syntara Ltd has announced the completion of patient recruitment for its randomized, double-blind, placebo-controlled Phase 2 clinical trial of SNT-4728 in patients with isolated REM Sleep Behaviour Disorder (iRBD). iRBD is estimated to affect around 2% of people over 50 years of age, and long-term studies suggest that up to 90% of individuals with iRBD subsequently develop a neurodegenerative disease such as Parkinson's disease or Dementia with Lewy bodies. The trial is designed to evaluate the potential impact of SNT-4728, Syntara's first-in-class neuro-targeted anti-inflammatory therapy, across two key dimensions: 1) Assessing whether SNT-4728 reduces neuroinflammation in brain regions implicated in the progression from iRBD to Parkinson's and related disorders, using advanced brain imaging; and 2) Exploring whether treatment with SNT-4728 improves the clinical symptoms of iRBD. The trial is being conducted in collaboration with leading academic centres and is supported by Parkinson's UK through its Parkinson's Virtual Biotech program. Top-line results from the study are expected in Q2 2026, making this one of five Syntara clinical studies with data readouts anticipated during the calendar year.

A positive outcome from this study could potentially change the field of iRBD and neurodegenerative disease treatment. Demonstrating an improvement in iRBD symptoms would offer immediate hope, while evidence of reduced neuroinflammation in key brain regions would provide important insight into whether intervening at the prodromal stage could influence the processes leading to Parkinson's and related disorders.